Problem
Information about hospital lots is dispersed between different systems and organizations, making it difficult to trace, check, and access a reliable history of each input
Solution
BioTracer creates a shared and verifiable history of batches of hospital supplies. The platform records transfers, receipts, acceptances, and refusals between chain organizations, allowing us to track the custody of each lot and consult its history through a QR Code. The events are recorded on blockchain, guaranteeing verifiable proof without requiring the replacement of the systems already used by the companies.
Business model
BioTracer adopts a B2B SaaS model, with recurring billing per organization. The initial plan will have an average ticket estimated at R$ 3.000 per month, including 3 operational users, 1 auditing profile, history of 12 months and support. This represents approximately R$ 36 thousand a year per customer. In the future, the model may evolve to plans by number of users, units, volume of tracked lots, and level of integration with existing systems.
Market
The global market for traceability (Track & Trace) solutions for healthcare was estimated at US$ 6,1 billions in 2025 And it must reach US$ 23,2 Billions even 2035, with annual growth of 16,2%. BioTracer operates in this market by offering traceability and custody history of hospital supplies along the supply chain.
Competitors
TraceLink, OPTEL Group, and Antares Vision are the main international competitors in pharmaceutical traceability. In Brazil, solutions such as ROMA, Sidicom, and Supra cover parts of this process. BioTracer differentiates itself by creating a shared history between organizations, recording transfers and accepted lot custody on the blockchain, without replacing the systems already used by companies.
Competitive differentiation
Unlike solutions focused solely on inventory, ERP or serialization, BioTracer records the transfer of custody of lots between organizations, with acceptance or refusal and verifiable blockchain history. The platform complements existing systems, offering shared traceability without requiring replacement.
Entry barrier
Our main barrier to entry is the network effect: the more manufacturers, distributors, and hospitals use BioTracer, the more valuable their shared custody history becomes. This ecosystem, added to the integrations, the accumulated history, and the knowledge of hospital flows, makes the solution progressively more difficult to replace or replicate.
Traction
BioTracer is still in its early stages, but it already has significant traction signs: we developed a functional MVP and the solution won two hackathons — Solana & Cursor and SuperTeamBR University Hackathon. These achievements represent external validation of the proposal, technical execution, and business potential. Currently, the next step is to convert this validation into pilots with hospitals and supply chain organizations.